Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication

Hiroto Kinoshita, Reiko Kunisaki, Hisae Yamamoto, Reikei Matsuda, Tomohiko Sasaki, Hideaki Kimura, Katsuaki Tanaka, Makoto Naganuma, Shin Maeda

研究成果: Article

25 引用 (Scopus)

抄録

Objective To investigate the short- and long-term efficacy and safety of infliximab (IFX) in intestinal Behçet's disease (BD) patients in a retrospective cohort study. Methods Among 43 consecutive patients with intestinal BD presenting at the same clinic, 15 with active disease and receiving standard treatment were given IFX infusions (5 mg/kg body weight) every eight weeks. The patients were clinically and endoscopically evaluated before treatment, then assessed after 10 weeks, 12 months and 24 months for a clinical response, defined as a significant improvement in intestinal symptoms and a reduced C-reactive protein (CRP) level. Results At week 10, 12 patients (80%) exhibited a response to IFX, with eight (53%) in remission with no intestinal symptoms and normal CRP levels. A response to IFX was maintained in seven of the 11 patients (64%) available at 12 months and in four of the eight patients (50%) available at 24 months. Of the seven patients receiving prednisolone at entry, five responders had their steroid doses reduced. Fulminant intestinal BD was predictive of an absence of response to IFX. The adverse effects comprised one infusion reaction and one case of fever, most likely related to IFX. Conclusion IFX is effective and safe in patients with refractory intestinal BD.

元の言語English
ページ(範囲)1855-1862
ページ数8
ジャーナルInternal Medicine
52
発行部数17
DOI
出版物ステータスPublished - 2013

Fingerprint

Intestinal Diseases
C-Reactive Protein
Infliximab
Prednisolone
Cohort Studies
Fever
Retrospective Studies
Steroids
Body Weight
Safety
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine

これを引用

Kinoshita, H., Kunisaki, R., Yamamoto, H., Matsuda, R., Sasaki, T., Kimura, H., ... Maeda, S. (2013). Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication. Internal Medicine, 52(17), 1855-1862. https://doi.org/10.2169/internalmedicine.52.0589

Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication. / Kinoshita, Hiroto; Kunisaki, Reiko; Yamamoto, Hisae; Matsuda, Reikei; Sasaki, Tomohiko; Kimura, Hideaki; Tanaka, Katsuaki; Naganuma, Makoto; Maeda, Shin.

:: Internal Medicine, 巻 52, 番号 17, 2013, p. 1855-1862.

研究成果: Article

Kinoshita, H, Kunisaki, R, Yamamoto, H, Matsuda, R, Sasaki, T, Kimura, H, Tanaka, K, Naganuma, M & Maeda, S 2013, 'Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication', Internal Medicine, 巻. 52, 番号 17, pp. 1855-1862. https://doi.org/10.2169/internalmedicine.52.0589
Kinoshita, Hiroto ; Kunisaki, Reiko ; Yamamoto, Hisae ; Matsuda, Reikei ; Sasaki, Tomohiko ; Kimura, Hideaki ; Tanaka, Katsuaki ; Naganuma, Makoto ; Maeda, Shin. / Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication. :: Internal Medicine. 2013 ; 巻 52, 番号 17. pp. 1855-1862.
@article{2b4444d65b49434c9254218e9b784468,
title = "Efficacy of infliximab in patients with intestinal Beh{\cc}et's disease refractory to conventional medication",
abstract = "Objective To investigate the short- and long-term efficacy and safety of infliximab (IFX) in intestinal Beh{\cc}et's disease (BD) patients in a retrospective cohort study. Methods Among 43 consecutive patients with intestinal BD presenting at the same clinic, 15 with active disease and receiving standard treatment were given IFX infusions (5 mg/kg body weight) every eight weeks. The patients were clinically and endoscopically evaluated before treatment, then assessed after 10 weeks, 12 months and 24 months for a clinical response, defined as a significant improvement in intestinal symptoms and a reduced C-reactive protein (CRP) level. Results At week 10, 12 patients (80{\%}) exhibited a response to IFX, with eight (53{\%}) in remission with no intestinal symptoms and normal CRP levels. A response to IFX was maintained in seven of the 11 patients (64{\%}) available at 12 months and in four of the eight patients (50{\%}) available at 24 months. Of the seven patients receiving prednisolone at entry, five responders had their steroid doses reduced. Fulminant intestinal BD was predictive of an absence of response to IFX. The adverse effects comprised one infusion reaction and one case of fever, most likely related to IFX. Conclusion IFX is effective and safe in patients with refractory intestinal BD.",
keywords = "Fulminant disease, Infliximab, Infusion interval, Intestinal Beh{\cc}et's disease, Prednisolone, Tumor necrosis factor- and alpha;",
author = "Hiroto Kinoshita and Reiko Kunisaki and Hisae Yamamoto and Reikei Matsuda and Tomohiko Sasaki and Hideaki Kimura and Katsuaki Tanaka and Makoto Naganuma and Shin Maeda",
year = "2013",
doi = "10.2169/internalmedicine.52.0589",
language = "English",
volume = "52",
pages = "1855--1862",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "17",

}

TY - JOUR

T1 - Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication

AU - Kinoshita, Hiroto

AU - Kunisaki, Reiko

AU - Yamamoto, Hisae

AU - Matsuda, Reikei

AU - Sasaki, Tomohiko

AU - Kimura, Hideaki

AU - Tanaka, Katsuaki

AU - Naganuma, Makoto

AU - Maeda, Shin

PY - 2013

Y1 - 2013

N2 - Objective To investigate the short- and long-term efficacy and safety of infliximab (IFX) in intestinal Behçet's disease (BD) patients in a retrospective cohort study. Methods Among 43 consecutive patients with intestinal BD presenting at the same clinic, 15 with active disease and receiving standard treatment were given IFX infusions (5 mg/kg body weight) every eight weeks. The patients were clinically and endoscopically evaluated before treatment, then assessed after 10 weeks, 12 months and 24 months for a clinical response, defined as a significant improvement in intestinal symptoms and a reduced C-reactive protein (CRP) level. Results At week 10, 12 patients (80%) exhibited a response to IFX, with eight (53%) in remission with no intestinal symptoms and normal CRP levels. A response to IFX was maintained in seven of the 11 patients (64%) available at 12 months and in four of the eight patients (50%) available at 24 months. Of the seven patients receiving prednisolone at entry, five responders had their steroid doses reduced. Fulminant intestinal BD was predictive of an absence of response to IFX. The adverse effects comprised one infusion reaction and one case of fever, most likely related to IFX. Conclusion IFX is effective and safe in patients with refractory intestinal BD.

AB - Objective To investigate the short- and long-term efficacy and safety of infliximab (IFX) in intestinal Behçet's disease (BD) patients in a retrospective cohort study. Methods Among 43 consecutive patients with intestinal BD presenting at the same clinic, 15 with active disease and receiving standard treatment were given IFX infusions (5 mg/kg body weight) every eight weeks. The patients were clinically and endoscopically evaluated before treatment, then assessed after 10 weeks, 12 months and 24 months for a clinical response, defined as a significant improvement in intestinal symptoms and a reduced C-reactive protein (CRP) level. Results At week 10, 12 patients (80%) exhibited a response to IFX, with eight (53%) in remission with no intestinal symptoms and normal CRP levels. A response to IFX was maintained in seven of the 11 patients (64%) available at 12 months and in four of the eight patients (50%) available at 24 months. Of the seven patients receiving prednisolone at entry, five responders had their steroid doses reduced. Fulminant intestinal BD was predictive of an absence of response to IFX. The adverse effects comprised one infusion reaction and one case of fever, most likely related to IFX. Conclusion IFX is effective and safe in patients with refractory intestinal BD.

KW - Fulminant disease

KW - Infliximab

KW - Infusion interval

KW - Intestinal Behçet's disease

KW - Prednisolone

KW - Tumor necrosis factor- and alpha;

UR - http://www.scopus.com/inward/record.url?scp=84883319786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883319786&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.52.0589

DO - 10.2169/internalmedicine.52.0589

M3 - Article

C2 - 23994973

AN - SCOPUS:84883319786

VL - 52

SP - 1855

EP - 1862

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 17

ER -